E D Crawford

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. ncbi request reprint Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer
    E David Crawford
    University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 21:27-32; discussion 33-4, 39. 2007
  2. doi request reprint Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Urology 75:502-9. 2010
  3. doi request reprint Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, 80045, USA
    BJU Int 108:1743-9. 2011
  4. doi request reprint Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, Colorado Electronic address
    J Urol 188:1726-31. 2012
  5. ncbi request reprint Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches
    E David Crawford
    University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora CO 80045, USA
    Oncology (Williston Park) 26:70-7. 2012
  6. ncbi request reprint Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW)
    A Barqawi
    Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 800010 0510, USA
    Int J Impot Res 17:370-4. 2005
  7. ncbi request reprint Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network
    A M Ziada
    University of Colorado Health Sciences Center, Denver, Colorado 80602, USA
    Cancer 91:1653-60. 2001
  8. ncbi request reprint Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
    A Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA
    Int J Impot Res 18:323-8. 2006
  9. ncbi request reprint Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values
    E D Crawford
    Division of Urology, University of Colorado Health Sciences Center, Denver 80262, USA
    Prostate 38:296-302. 1999
  10. ncbi request reprint Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer
    J T Batuello
    Artificial Neural Networks in CaP Project and the, Denver, Colorado 80209, USA
    Urology 57:481-5. 2001

Collaborators

Detail Information

Publications72

  1. ncbi request reprint Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer
    E David Crawford
    University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 21:27-32; discussion 33-4, 39. 2007
    ..In this review, we present the current status of our knowledge about this procedure and the most important challenges that need to be addressed. We also present the initial results with this approach at our center...
  2. doi request reprint Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Urology 75:502-9. 2010
    ..Particular emphasis is placed on the design of the second large-scale trial of a 5alpha-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial...
  3. doi request reprint Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, 80045, USA
    BJU Int 108:1743-9. 2011
    ..This study examines a larger number of men in a diverse US population to determine the prognostic value of a man's baseline or first PSA...
  4. doi request reprint Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, Colorado Electronic address
    J Urol 188:1726-31. 2012
    ..We investigated the value of the PCA3 (prostate cancer gene 3) urine test in predicting the likelihood of diagnosis of cancer before biopsy...
  5. ncbi request reprint Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches
    E David Crawford
    University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora CO 80045, USA
    Oncology (Williston Park) 26:70-7. 2012
    ..The treatment paradigm for these patients is rapidly evolving, with future study needed to define the optimal sequencing and potential combinations of these new agents...
  6. ncbi request reprint Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW)
    A Barqawi
    Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 800010 0510, USA
    Int J Impot Res 17:370-4. 2005
    ..Moreover, race appears to constitute another neglected potential risk factor, which should be investigated further in future studies...
  7. ncbi request reprint Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network
    A M Ziada
    University of Colorado Health Sciences Center, Denver, Colorado 80602, USA
    Cancer 91:1653-60. 2001
    ..Continued investigation of this approach with larger data sets seems warranted...
  8. ncbi request reprint Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
    A Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA
    Int J Impot Res 18:323-8. 2006
    ..Current recommendations are to exclude prostate cancer before initiating TRT in men over age 40 and to closely monitor men in the first year of testosterone replacement, followed by observation in subsequent years...
  9. ncbi request reprint Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values
    E D Crawford
    Division of Urology, University of Colorado Health Sciences Center, Denver 80262, USA
    Prostate 38:296-302. 1999
    ..0 ng/ml or an age-specific reference range (ASRR) as an abnormal cutoff PSA value...
  10. ncbi request reprint Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer
    J T Batuello
    Artificial Neural Networks in CaP Project and the, Denver, Colorado 80209, USA
    Urology 57:481-5. 2001
    ..The risk curve provides a clinically useful tool that can be used to give patients a realistic assessment of their risk of LN spread...
  11. doi request reprint A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer
    Thomas W Flaig
    Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA
    Prostate 70:848-55. 2010
    ..The purpose of the current trial was to determine the tissue and blood effects of high-dose silybin-phytosome in prostate cancer patients...
  12. ncbi request reprint Radiation therapy after radical prostatectomy
    Ali M Ziada
    Division of Urology, University of Colorado, Denver, CO, USA
    ScientificWorldJournal 4:377-81. 2004
  13. ncbi request reprint Terazosin, doxazosin, and prazosin: current clinical experience
    B Akduman
    Section of Urologic Oncology, Department of Radiation Oncology, Colorado Health Science Center, Denver, Colorado 80262, USA
    Urology 58:49-54. 2001
    ..Pharmacokinetic activity, mode of action, clinical efficacy, and side effects of the selective alpha(1)-receptor blockers terazosin, doxazosin, and prazosin are reviewed...
  14. doi request reprint A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer
    E D Crawford
    Department of Urologic Oncology, University of Colorado, Denver, CO, USA
    Prostate Cancer Prostatic Dis 13:162-7. 2010
    ..With or without treatment, prostate cancer is a significant clinical and economic burden to society. New strategies for treatment or cancer prevention could play a role in reducing this burden...
  15. ncbi request reprint Focal therapy in prostate cancer: future trends
    Al Barqawi
    University of Colorado Health Sciences Center, 4200 E 9th Ave, C 319, Denver, Colorado 80262, USA
    BJU Int 95:273-4. 2005
  16. ncbi request reprint Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy
    Al Baha Barqawi
    Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:872-6. 2003
    ..To evaluate the efficacy and tolerability of combined finasteride and low-dose flutamide for prostate-specific antigen (PSA)-only recurrence after definitive therapy and to determine the predictors of recurrence-free survival...
  17. ncbi request reprint The management of high risk prostate cancer
    Bulent Akduman
    Section of Urologic Oncology, Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 169:1993-8. 2003
    ..There is no consensus on the treatment of these groups of patients. The role of radiotherapy, hormonal therapy or chemotherapy must be defined...
  18. ncbi request reprint Use of artificial neural networks in prostate cancer
    A Errejon
    ANNs in CaP Project, Denver, Colorado 80209, USA
    Mol Urol 5:153-8. 2001
    ..We review the basic concepts behind ANNs and examine the role of this technology in selected applications in prostate cancer research...
  19. ncbi request reprint The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer
    A Barqawi
    University of Colorado Cancer Center, and Urologic Oncology, University of Colorado Health Sciences Center, Denver, CO 80261, USA
    BJU Int 92:695-8. 2003
    ....
  20. ncbi request reprint Testosterone replacement therapy and the risk of prostate cancer: a perspective view
    A B Barqawi
    Section Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Int J Impot Res 17:462-3. 2005
    ..This perspective continues the debate, and offers a unique perspective from the vantage point of a uro-oncologist...
  21. ncbi request reprint Prostate cancer update
    S S Wilson
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Minerva Urol Nefrol 55:199-204. 2003
    ..Its diagnosis, evaluation, and treatment therapies are constantly evolving. This paper summarizes and clarifies the most up-to-date information on prostate cancer prevention and treatment...
  22. doi request reprint Dutasteride: novel milestones in prostate cancer chemoprevention
    K O Rove
    University of Colorado, Denver, Colorado, USA
    Drugs Today (Barc) 47:135-44. 2011
    ....
  23. ncbi request reprint Surgical management of prostate cancer: optimizing patient selections and clinical outcome
    Paul D Maroni
    Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, Denver, 80252, USA
    Surg Oncol Clin N Am 14:301-19. 2005
  24. ncbi request reprint The current use and future trends of focal surgical therapy in the management of localized prostate cancer
    Al B Barqawi
    Urologic Oncology Department, School of Medicine, University of Colorado Health Science Center, Denver, CO, USA
    Cancer J 13:313-7. 2007
    ..In addition, we will discuss future promising tools in MIT such as photodynamic therapy and the target focal therapy approach as a new trend for the treatment of organ-confined low-volume disease...
  25. ncbi request reprint Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy
    E David Crawford
    Radiation Oncology, Department of Pathology, University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO 80045, USA
    BJU Int 96:999-1004. 2005
    ..To identify the precise location of prostate cancer within the gland and thus possibly permit more aggressive therapy of the lesion, while potentially sparing the noncancerous gland from ablative therapy...
  26. ncbi request reprint Minimally invasive surgery in prostate cancer: current and future perspectives
    Bulent Akduman
    University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, Aurora, Colorado 80010, USA
    Cancer J 11:355-61. 2005
    ..In this review we critically discuss the current knowledge and future perspectives of minimally invasive treatment in prostate cancer...
  27. ncbi request reprint Testosterone and the prostate: implications for the treatment of hypogonadal men
    Joshua D Holyoak
    Division of Urology, University of Missouri Health Sciences Center, Columbia, MO 65212, USA
    Curr Urol Rep 9:500-5. 2008
    ..Patients undergoing TRT should be monitored carefully for any evidence of prostatic disease...
  28. ncbi request reprint Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
    M Scott Lucia
    Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
    J Natl Cancer Inst 99:1375-83. 2007
    ..We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size...
  29. doi request reprint Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Science Center, Mail Stop 8117, P O Box 6511, Aurora, CO 80045 0511, USA
    J Clin Oncol 26:1532-6. 2008
    ..Southwest Oncology Group (SWOG) study 9921 is a randomized, phase III, intergroup study to define the role of adjuvant chemotherapy in patients with high-risk prostate cancer...
  30. doi request reprint The benefits of early androgen blockade
    Paul D Maroni
    The University of Colorado at Denver and Health Sciences Center, Academic Office One Bldg, Aurora, CO 80045, USA
    Best Pract Res Clin Endocrinol Metab 22:317-29. 2008
    ..This review concentrates on high-level evidence to address common clinical situations in advanced and metastatic prostate cancer. Additionally, the side-effects of androgen blockade have become increasingly visible and relevant...
  31. ncbi request reprint Intermediate- to high-risk prostate cancer patient treated with radiation therapy
    E David Crawford
    University of Colorado Health Sciences Center, Denver, USA
    Oncology (Williston Park) 18:1105-10. 2004
  32. ncbi request reprint Early versus late hormonal therapy: debating the issues
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center, Denver, Colorado 80010, USA
    Urology 61:8-13. 2003
    ..Thus, accumulating evidence provides a rationale for continued investigation into the use of early hormonal therapy in selected patients...
  33. ncbi request reprint Prostate cancer chemoprevention: an overview of United States trials
    Albaha Barqawi
    Division of Urologic Oncolgy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 171:S5-8; discussion S9. 2004
    ..We review the current status of clinical trials investigating the use of interventions designed to reduce the risk of prostate cancer...
  34. ncbi request reprint Recent advances in hormonal therapy for advanced prostate cancer
    Siam Oottamasathien
    Department of Surgery, Division of Urology, University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:1047-52; discussion 1054-8. 2003
    ..Although hormonal therapy is an important treatment modality for advanced prostate cancer, long-term treatment carries significant side effects that need to be considered...
  35. ncbi request reprint Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
    Ian M Thompson
    Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
    N Engl J Med 350:2239-46. 2004
    ..We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less...
  36. doi request reprint High-intensity focused ultrasound: ready for primetime
    Kyle O Rove
    Division of Urology, University of Colorado Anschutz Medical Campus, 12631 East 17th Avenue, Mailstop C302, Aurora, CO 80045, USA
    Urol Clin North Am 37:27-35, Table of Contents. 2010
    ..The HIFU technique, its mechanism of action, patient selection, current efficacy studies, complications, follow-up after HIFU treatment, and future developments are discussed...
  37. ncbi request reprint Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:13-9. 2003
    ....
  38. ncbi request reprint Three different strategies for real-time prostate capsule volume computation from 3-D end-fire transrectal ultrasound
    Albaha B Barqawi
    University of Colorado Health Science Center, Aurora, CO 80010, USA
    Conf Proc IEEE Eng Med Biol Soc 2007:816-8. 2007
    ..The mean volumes using the least square, level set and DDC techniques were 15.84 cc, 15.55 cc and 16.33 cc, respectively. We validated the methods by calculating the volume with GT and we got an average volume of 15...
  39. doi request reprint The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions
    Natalie J Serkova
    Department of Anesthesiology and Radiology, Biomedical MRI MRS, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Prostate 68:620-8. 2008
    ..In this study, proton nuclear magnetic resonance spectroscopy ((1)H-NMRS) is used to assess potential metabolic markers of prostate cancer (PCa) in human expressed prostatic secretions (EPS)...
  40. ncbi request reprint Epidemiology of prostate cancer
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:3-12. 2003
    ..In contrast, mortality rates for men diagnosed with localized or regional disease increased gradually during most of the 1990s before decreasing slightly among white men and reaching plateaus among African Americans...
  41. ncbi request reprint Emerging role of HIFU as a noninvasive ablative method to treat localized prostate cancer
    Al B Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurura, CO 80010, USA
    Oncology (Williston Park) 22:123-9; discussion 129, 133, 137 passim. 2008
    ..This review summarizes current knowledge about the basic principles of HIFU and its reported efficacy and morbidity in clinical series published since 2000...
  42. ncbi request reprint Prostate cancer. Introduction
    E David Crawford
    Division of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:1-2. 2003
  43. doi request reprint PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Eur Urol 54:262-73. 2008
    ..Despite the substantive societal impact of prostate cancer, the medical community is currently divided on the balance between benefit and harm of screening for prostate cancer using prostate-specific antigen (PSA)...
  44. ncbi request reprint Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
    L Michael Glode
    Oncology Urology Department, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer 98:1643-8. 2003
    ....
  45. doi request reprint Understanding the epidemiology, natural history, and key pathways involved in prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Science Center, Denver, Colorado, USA
    Urology 73:S4-10. 2009
    ..A substantial research effort has recently focused on understanding the pathways involved in the disease's emergence and progression, particularly the 5alpha-reductase pathway...
  46. ncbi request reprint A 72-year-old man with prostate cancer
    E David Crawford
    University of Colorado Health Sciences Center, Denver, USA
    Oncology (Williston Park) 16:1014-6, 1119-21. 2002
  47. ncbi request reprint The role of LHRH antagonists in the treatment of prostate cancer
    E David Crawford
    Department of Urology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    Oncology (Williston Park) 23:626-30. 2009
    ..Presently, degarelix is the only LHRH antagonist approved for the treatment of advanced prostate cancer...
  48. ncbi request reprint SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study
    Catherine E Klein
    University of Colorado, Denver, Colorado, USA
    Prostate 52:264-8. 2002
    ..Topotecan is a new topoisomerase-1 inhibitor whose early investigation suggested possible activity in hormone-refractory prostate cancer...
  49. ncbi request reprint A 42-year-old woman with breast cancer
    E David Crawford
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:614; discussion 615-20. 2003
    ..At this point, we recommend tamoxifen, with consideration to adding goserelin (Zoladex) if the patient does not remain amenorrheic. The patient chose to enter the Intergroup trastuzumab trial...
  50. doi request reprint Targeted focal therapy for prostate cancer: a review
    Amy H Hou
    University of Colorado Health Sciences Center, Department of Urology, Aurora, Colorado 80045, USA
    Curr Opin Urol 19:283-9. 2009
    ..In this review, we will discuss targeted focal therapy (TFT) using the modalities of cryotherapy or high intensity focused ultrasound as an alternate treatment for low-risk prostate cancers...
  51. ncbi request reprint Should routine screening for prostate-specific antigen be recommended?
    Siam Oottamasathien
    Division of Urology, Box c319, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Arch Intern Med 163:661-2; discussion 666. 2003
  52. ncbi request reprint Screening for prostate cancer
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, Denver, CO, USA
    Clin Prostate Cancer 3:21-5. 2004
    ..These measures include prevention, screening, improved curative treatment, and the transformation of an acute lethal disease to a chronic, tolerable one. This summary focuses on the screening aspects of prostate cancer...
  53. ncbi request reprint Controversies regarding screening for prostate cancer
    E David Crawford
    Department of Urologic Oncology, University of Colorado, Denver, CO 80010, USA
    BJU Int 100:5-7. 2007
  54. ncbi request reprint High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade
    Zinelabidine Abouelfadel
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Prostate Cancer 1:115-7. 2002
    ..Continued screening for prostate cancer is resulting in the diagnosis of more unfavorable cancers...
  55. ncbi request reprint Artificial neural networks for predictive modeling in prostate cancer
    Eduard J Gamito
    University of Colorado Health Sciences Center, C 314, 200 East 9th Avenue, Denver, CO 80262, USA
    Curr Oncol Rep 6:216-21. 2004
    ..This article provides an overview of the theoretical basis of ANNs, how they function, their strengths and limitations, and examples of how ANNs have been used to develop predictive models for the management of prostate cancer...
  56. ncbi request reprint Screening for prostate cancer: current recommendations
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, 1665 North Ursula, Aurora, CO 80010, USA
    Urol Clin North Am 31:219-26. 2004
    ..It is hoped that prospective, randomized, long-term screening studies, such as the PLCO and ERSCP trials, will show improved survival using the admittedly imperfect PSA marker in prostate cancer screening...
  57. ncbi request reprint Genitourinary malignancies
    Shandra S Wilson
    Department of Urologic Oncology, Anschuz Cancer, Aurora, CO 80010, USA
    Cancer Chemother Biol Response Modif 22:485-513. 2005
  58. ncbi request reprint Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models
    Priya N Werahera
    Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Hum Pathol 35:798-807. 2004
    ..Moreover, our 3-dimensional computer modeling system improves upon other systems: It is more than a simple extension of the planimetric technique, and it is able to demarcate clearly the boundaries of Gleason grades just 1 grade apart...
  59. ncbi request reprint Preventing and treating the complications of hormone therapy
    Ravi J Kumar
    Urologic Oncology, University of Colorado Health Sciences Center, 4200 East 9th Avenue C 319, Denver, CO 80262, USA
    Curr Urol Rep 6:217-23. 2005
    ....
  60. ncbi request reprint PSA testing: what is the use?
    E David Crawford
    University of Colorado, Denver, CO 80262, USA
    Lancet 365:1447-9. 2005
  61. ncbi request reprint Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program
    Al Baha Barqawi
    Section of Urologic Oncology, University of Colorado Health Science Center School of Medicine, Denver, Colorado, USA
    Urology 65:708-12. 2005
    ..To assess the effect of aging and body mass index (BMI) on both serum total prostate-specific antigen (tPSA) and complexed PSA (cPSA) from the results of the 2003 Prostate Cancer Awareness Week national screening database...
  62. ncbi request reprint A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    J Urol 175:533-6. 2006
    ..The safety, efficacy and pharmacokinetics of LA-2585, a new 6-month subcutaneous depot of leuprolide acetate (Atrix Laboratories, Fort Collins, Colorado) were investigated in patients with prostate cancer...
  63. ncbi request reprint Controversies of androgen ablation therapy for metastatic prostate cancer
    Shandra S Wilson
    Department of Urologic Oncology, 1665 North Ursula, Aurora, CO 80010, USA
    Curr Pharm Des 12:799-805. 2006
    ....
  64. ncbi request reprint The association of time of day and serum testosterone concentration in a large screening population
    E David Crawford
    Surgery and Radiation Oncology, Section of Urologic Oncology, UCHSC, Aurora, CO, USA
    BJU Int 100:509-13. 2007
    ....
  65. ncbi request reprint Prostate cancer in a man with multiple previous cancers
    Thomas Flaig
    University of Colorado, Health Sciences Center, Aurora, Colorado, USA
    Oncology (Williston Park) 21:611-4. 2007
  66. ncbi request reprint Herbal and vitamin supplement use in a prostate cancer screening population
    Albaha Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 63:288-92. 2004
    ....
  67. ncbi request reprint The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Am J Clin Oncol 29:517-23. 2006
    ..This review will analyze the current state of knowledge of LUTS secondary to RT for prostate cancer and review treatment options for this complication...
  68. ncbi request reprint Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma
    Thomas D Denberg
    University of Colorado at Denver and Health Sciences Center, Denver, CO, USA
    BJU Int 98:335-40. 2006
    ....
  69. ncbi request reprint A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, CO 80045 0511, USA
    Cancer 107:266-74. 2006
    ..Preclinical data from prostate cancer cell lines suggested a synergistic effect of these therapies...
  70. ncbi request reprint Screening for prostate cancer in 2006: PSA in the 21st century
    Paul D Maroni
    Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, USA
    N C Med J 67:136-9. 2006
  71. ncbi request reprint Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, Washington, DC, USA
    J Urol 175:1286-90; discussion 1290. 2006
    ..A large fraction of screened men have low (less than 2 ng/ml) initial PSA. The yield over time of positive PSA screens (ie more than 4 ng/ml) in these men has not been well characterized in large cohorts in the United States...
  72. ncbi request reprint The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
    Ali Ziada
    UCHSC, 4200 E 9th Ave C 319, Denver, CO, USA
    Prostate 60:332-7. 2004
    ..To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin) in the treatment of advanced hormone-refractory prostate cancer (HRPC)...